Sawai Pharmaceutical and Pfizer Japan said on October 25 that their generic versions of the cholesterol fighter Crestor (rosuvastatin) have won approval for familial hypercholesterolemia (FH), putting them on a level playing field with the originator before their anticipated listing…
To read the full story
Related Article
- More Crestor Generics Now on Equal Footing with Originator
July 20, 2023
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





